MYO

Myomo Inc. (MYO) | Rumor.io

Myomo

MYO

Attention (50-day avg)0%

Attention rank (50-day avg)#2,458

Bullish sentiment (50-day avg)95%

Price to earnings ratio-4.27

Market capitalization61.8M

Earnings per share-0.34

Dividend yield (TTM)—

Revenue (annual)40.9M

Net income (annual)-15.6M

Social

What share of all stock conversation is about MYO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 24

Insiders have bought 500k shares in the last 6 months, while selling 17,500 shares recently, despite the stock being up 125% from when it was considered a good short.
The company's 20-day moving average (dma) is 1.3, and some are targeting a price of $8.40.
The company is in its "death throes" and may return to its forward revenue multiple, with some speculating it could drop to $1, despite recent gains.

Generated by AI

Sentiment

Of the messages about MYO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +5	82.44% -2.39
Bearish	—	—	0% -5	17.56% +2.39

Bullish· Oct 9

$MYO has seen significant trading volume, with 8 million shares traded in one day, indicating strong market interest.
The stock has shown resilience, with a small cool-off after a run followed by a steady upward movement, suggesting a potential bounce at the SMA50.
$MYO has a strong institutional ownership, with over 50% of the company owned by institutions, which may contribute to a $10 price target and ongoing bullish momentum.

Bearish· Jun 12

The stock has broken a bearish flag pattern, indicating a potential downward trend.
The 10-day moving average is below the 50-day moving average, a bearish indicator.
The stock has already dropped significantly from its previous highs, with some investors potentially facing losses of 25% or more.

Generated by AI

Topics

Of the messages about MYO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	22.89%
Announcements	—	—	—	29.88%
Analysts	—	—	—	1.93%
Earnings	—	—	—	3.37%
Macro	—	—	—	41.93%
Controversies	—	—	—	0%

Earnings· Aug 7

Myomo, Inc. ($MYO) reported Q2 revenue of $632,369, up from $313,179 in Q1.
The company hosted a Q2 earnings call on the specified date and time, which was streamed live and available on replay.
Myomo's Q2 earnings results missed expectations by $0.02 EPS.

Announcements· Dec 4

Myomo, Inc. has built a unique economic moat in a niche market with its EMG-powered upper-limb robotic orthosis.
The company's Q3 2025 earnings showed revenue of $10.1M, a 10% YoY increase, with 186 MyoPro units delivered and 229 orders/authorizations.
Myomo's patient pipeline continues to expand, with 1,669 patients in process, indicating strong demand for its products.

Technical Analysis· Mar 13

The 5-minute chart for $MYO is "crystal clear" and suggests a buy opportunity around 78 cents.
A breakout for $MYO is expected, potentially driven by earnings on Monday, which could send the price past $1.
The weekly chart for $MYO is showing a potentially bullish trend, with the price curling and ready to break above the 20-day EMA, which could lead to a price of $2 or more.

Generated by AI

Community

Of the messages about MYO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	73.68%	32.77%
Newcomers	—	—	26.32%	67.23%

Regulars· Aug 6

The regulars are focused on the company's progress, with one user noting a "solid Q2 earnings report" and another highlighting the company's ability to grow despite losses.
The regulars are also discussing the company's growth prospects, with one user predicting that future earnings will be greater and another noting that the company is expected to accelerate growth in 2027.
The regulars are concerned about the company's profitability, with one user noting that the company is still borrowing to pay its losses and another warning that dilution is inevitable given the losses.

Newcomers· Mar 9

Newcomers to discussing MYO are excited about the potential for increased patient access to MyoPro, a wearable device that can be covered by commercial insurance, Medicare, and Medicaid.
The partnership between Myomo and Elevance Health is seen as a significant development, with many newcomers speculating about the potential benefits for both companies.
The announcement of the partnership between Myomo and Elevance Health is being viewed as a positive catalyst for the MYO stock, with some newcomers expecting a boost in the asset's value.

Generated by AI

BURLINGTON, Mass., September 01, 2026--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced its participation at the H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026 at the Lotte Palace Hotel in New York. Myomo’s President and Chief Executive Officer Paul Gudonis and Chief Financial Offic

28d agoYahoo Finance

Also Discussed

Investors talking about MYO also mention

#	Name	Attention
1	My Size, Inc.MYSZ	0%new
2	Anixa Biosciences, Inc.ANIX	0%new
3	YTEN - Yield10 Bioscience, Inc.	——
4	Ekso Bionics Holdings, Inc.EKSO	0%new
5	Daxor CorporationDXR	0%0
6	PIXY - ShiftPixy, Inc.	——
7	Nanoviricides Inc.NNVC	0%0
8	Lm Funding America Inc.LMFA	0%new
9	InspireMD, Inc.NSPR	0%new
10	ZW Data Action Technologies Inc.CNET	0%0

Myomo Inc.

Healthcare
Medical Devices

Myomo Inc. is a medical robotics company that develops and markets myoelectric orthotic devices for people with neuromuscular disorders and upper-limb paralysis. Its flagship MyoPro product line is a powered arm brace designed to support weakened or paralyzed arms and hands by detecting the user’s own muscle signals through non-invasive sensors. The company serves patients recovering from or living with conditions such as stroke, spinal cord injury, brachial plexus injury, traumatic brain injury, ALS, and multiple sclerosis. Myomo Inc. sells its devices through orthotics and prosthetics providers, direct clinical and insurance-based channels, the Veterans Administration, and selected distributors in the United States and international markets. The company focuses on restoring upper-limb function, supporting daily activities, and improving mobility for individuals with neurological and muscular impairments.

Website

Location

45 Blue Sky Dr.

Burlington, MA, 01803

United States

Social

What share of all stock conversation is about MYO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 24

Insiders have bought 500k shares in the last 6 months, while selling 17,500 shares recently, despite the stock being up 125% from when it was considered a good short.
The company's 20-day moving average (dma) is 1.3, and some are targeting a price of $8.40.
The company is in its "death throes" and may return to its forward revenue multiple, with some speculating it could drop to $1, despite recent gains.

Generated by AI

Sentiment

Of the messages about MYO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +5	82.44% -2.39
Bearish	—	—	0% -5	17.56% +2.39

Bullish· Oct 9

$MYO has seen significant trading volume, with 8 million shares traded in one day, indicating strong market interest.
The stock has shown resilience, with a small cool-off after a run followed by a steady upward movement, suggesting a potential bounce at the SMA50.
$MYO has a strong institutional ownership, with over 50% of the company owned by institutions, which may contribute to a $10 price target and ongoing bullish momentum.

Bearish· Jun 12

The stock has broken a bearish flag pattern, indicating a potential downward trend.
The 10-day moving average is below the 50-day moving average, a bearish indicator.
The stock has already dropped significantly from its previous highs, with some investors potentially facing losses of 25% or more.

Generated by AI

Topics

Of the messages about MYO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	22.89%
Announcements	—	—	—	29.88%
Analysts	—	—	—	1.93%
Earnings	—	—	—	3.37%
Macro	—	—	—	41.93%
Controversies	—	—	—	0%

Earnings· Aug 7

Myomo, Inc. ($MYO) reported Q2 revenue of $632,369, up from $313,179 in Q1.
The company hosted a Q2 earnings call on the specified date and time, which was streamed live and available on replay.
Myomo's Q2 earnings results missed expectations by $0.02 EPS.

Announcements· Dec 4

Myomo, Inc. has built a unique economic moat in a niche market with its EMG-powered upper-limb robotic orthosis.
The company's Q3 2025 earnings showed revenue of $10.1M, a 10% YoY increase, with 186 MyoPro units delivered and 229 orders/authorizations.
Myomo's patient pipeline continues to expand, with 1,669 patients in process, indicating strong demand for its products.

Technical Analysis· Mar 13

The 5-minute chart for $MYO is "crystal clear" and suggests a buy opportunity around 78 cents.
A breakout for $MYO is expected, potentially driven by earnings on Monday, which could send the price past $1.
The weekly chart for $MYO is showing a potentially bullish trend, with the price curling and ready to break above the 20-day EMA, which could lead to a price of $2 or more.

Generated by AI

Community

Of the messages about MYO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	73.68%	32.77%
Newcomers	—	—	26.32%	67.23%

Regulars· Aug 6

The regulars are focused on the company's progress, with one user noting a "solid Q2 earnings report" and another highlighting the company's ability to grow despite losses.
The regulars are also discussing the company's growth prospects, with one user predicting that future earnings will be greater and another noting that the company is expected to accelerate growth in 2027.
The regulars are concerned about the company's profitability, with one user noting that the company is still borrowing to pay its losses and another warning that dilution is inevitable given the losses.

Newcomers· Mar 9

Newcomers to discussing MYO are excited about the potential for increased patient access to MyoPro, a wearable device that can be covered by commercial insurance, Medicare, and Medicaid.
The partnership between Myomo and Elevance Health is seen as a significant development, with many newcomers speculating about the potential benefits for both companies.
The announcement of the partnership between Myomo and Elevance Health is being viewed as a positive catalyst for the MYO stock, with some newcomers expecting a boost in the asset's value.

Generated by AI

Myomo

Social

Aug 24

Bullish· Oct 9

Bearish· Jun 12

Earnings· Aug 7

Announcements· Dec 4

Technical Analysis· Mar 13

Regulars· Aug 6

Newcomers· Mar 9

Myomo Q2 2026 Earnings Call Transcript

Myomo at H.C. Wainwright conference: referral shift drives growth

Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Myomo CMO Harry Kovelman sells $30,329 in stock

Myomo chief medical officer sells $29,895 in shares

Myomo Q2 Earnings Call Highlights

Also Discussed

Myomo Inc.

Company Information

Location

Myomo Q2 2026 Earnings Call Transcript

Myomo at H.C. Wainwright conference: referral shift drives growth

Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Myomo CMO Harry Kovelman sells $30,329 in stock

Myomo chief medical officer sells $29,895 in shares

Myomo Q2 Earnings Call Highlights

Also Discussed

Social

Aug 24

Bullish· Oct 9

Bearish· Jun 12

Earnings· Aug 7

Announcements· Dec 4

Technical Analysis· Mar 13

Regulars· Aug 6

Newcomers· Mar 9